The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for March 2009. One of the drugs reviewed is atomoxetin (Strattera), a SNRI used for the treatment of ADHD. These are the recommendations:
Advice for healthcare professionals:
• At normal doses, atomoxetine can be associated with treatment-emergent psychotic or manic symptoms (eg, hallucinations, delusional thinking, mania, or agitation) in children and adolescents without a history of psychotic illness or mania.
• If such symptoms occur , consideration should be given to a possible causal role of atomoxetine and discontinuation of treatment.
• It remains possible that atomoxetine might exacerbate pre-existing psychotic or manic symptoms.
Fid
Read the new book, The Evidence, However, Is Clear...The Seroxat Scandal
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
"It's not about what they tell you, it's about what they don't."
~ Bob Fiddaman, Author, Blogger, Researcher, Recipient of two Human Rights awards
Researching drug company and regulatory malfeasance for over 16 years
Humanist, humorist
Subscribe to:
Post Comments (Atom)
Please contact me if you would like a guest post considered for publication on my blog.
No comments: